Purine analogues in advanced T-cell lymphoid malignancies. Semin Hematol 2006 Apr;43(2 Suppl 2):S27-34
Date
03/22/2006Pubmed ID
16549112DOI
10.1053/j.seminhematol.2005.12.010Scopus ID
2-s2.0-33645007850 (requires institutional sign-in at Scopus site) 8 CitationsAbstract
T-cell lymphomas account for 10% to 15% of all lymphoid malignancies. In advanced stages of T-cell lymphoma, single or multiagent chemotherapy and bioimmunotherapeutic agents have been used. Purine analogues have demonstrated activity in both refractory cutaneous T-cell lymphoma and peripheral T-cell lymphoma with response rates ranging from 20% to 70%. Response rates have been higher with pentostatin (60%) than with the other compounds in this class. The potential limitation to this therapy is the prolonged immunosuppression, which increases the risk of opportunistic injections in patients who are already at heightened risk for infections. Patients should be monitored closely with CD4 counts and surveillance for opportunistic infections. Future studies of purine analogues should evaluate patients who are less heavily pretreated and combination therapy with other agents such as alemtuzumab should be investigated in order to prolong the duration of disease remission.
Author List
Kurzrock R, Ravandi FAuthor
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
HumansLeukemia, T-Cell
Lymphoma, T-Cell
Purine Nucleosides
Treatment Outcome